Target intelligence / Profile preview

Marek’s disease virus antigen (MDV antigen)

Target
MDV antigen
Molecular classification
Other (multiple protein antigens; includes viral phosphoprotein pp38, oncoprotein Meq, envelope glycoproteins such as gC)
01

Overview

Marek’s disease virus antigens refer to a collection of proteins encoded by Marek’s disease virus (MDV), an alphaherpesvirus that infects chickens and causes T-cell lymphomas and immunosuppression. Notable antigens include the phosphoprotein pp38 (associated with viral transformation and always present in transformed cells), the Meq oncoprotein (homologous to the Jun/Fos family and essential for tumor development), and envelope glycoprotein C (gC, important for viral spread and immune evasion). These antigens serve as important immunological and diagnostics markers, and form the basis for vaccine development, but they do not correspond to a single therapeutic target like a host receptor or enzyme. The term "Marek's disease virus antigens" is therefore too broad and imprecise for structured target information, as it encompasses multiple proteins with divergent molecular features and functions, rather than a single defined target molecule.

Other names
Marek’s disease virus antigenMDV antigenMarek’s disease viral antigenSpecific MDV proteins are often called pp38, Meq (oncoprotein), glycoprotein C (gC), etc.
02

Mechanism of action

Not applicable for drugs, but for vaccines: induction of protective immune responses (mainly via live-attenuated vaccines, which present MDV antigens to elicit immunity)

03

Biological functions

Immune response (MDV antigens elicit strong host immune responses)Tumor transformation (Meq and pp38 are associated with transformation and oncogenesis)Viral replication and latency (envelope glycoproteins are necessary for infection and spread)
04

Disease associations

Infection (Marek’s disease)Cancer (lymphoma, as MDV induces T-cell lymphomas in chickens)
05

Safety considerations

Vaccination with live-attenuated strains can theoretically lead to recombination or insufficient protection, leading to emergence of more virulent MDV strainsNo known direct safety issues for therapeutic targeting, as these are viral proteins, not human targets
06

Interacting drugs

None (no approved drugs targeting these antigens; control is based on vaccination rather than chemicals/antivirals)
07

Biomarkers

Expression of pp38, Meq, and gC in tissues/cell lines used as biomarkers for infection and tumor transformation status in chickensMDV DNA/RNA and antigen detection assays are used in diagnostics

Beyond the preview

Go deeper on Marek’s disease virus antigen (MDV antigen).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Marek’s disease virus antigen (MDV antigen).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call